Publications
-
Phase 1 safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824
Citation: Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS Clinical Trials Group A5306 Study Team. Phase 1 safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52. doi: 10.1128/AAC.03332-14.
Date: 09/15/2014
Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial
Citation: Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, Rana A, Nyirenda M, Kayoyo VM, Samaneka W, Joglekar A, Celentano D, Martinez A, Remmert JE, Nair A, Lalloo UG, Kumarasamy N, Hakim J, Campbell TB; PEARLS (ACTG A5175) Study Team. Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One. 2014 Aug 25;9(8):e104178. doi: 10.1371/journal.pone.0104178. eCollection 2014. PMID: 25153084; PMCID: PMC4143224
Date: 08/25/2014
Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV
Citation: Mave V, Suryavanshi N, Kulkarni V, Balasubramanian U, Jadhav A, Bhattacharya D, Patil S, Khandekar M, Paranjape R, Tripathy S, Kinikar A, Bharadwaj R, Bhosale RA, Sambarey P, Jamkar A, Sastry J, Bollinger RC, Gupta A for the SWEN India Study team. Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV. HIV Med. 2014 Jul;15(6):347-54. doi: 10.1111/hiv.12120. Epub 2014 Jan 14. PMID: 24422893. PMCID: PMC4055515.
Date: 07/15/2014
Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study
Citation: Haley DF, Golin C, El-Sadr W, Hughes JP, Wang J, Roman Isler M, Mannheimer S, Kuo I, Lucas J, DiNenno E, Justman J, Frew PM, Emel L, Rompalo A, Polk S, Adimora AA, Rodriquez L, Soto-Torres L, Hodder S. Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study. J Womens Health (Larchmt). 2014 Jun;23(6):541-51. doi: 10.1089/jwh.2013.4654. Epub 2014 Apr 17. PMID: 24742266; PMCID: PMC4046355
Date: 06/15/2014
Substance use patterns and factors associated with changes over time in a cohort of heterosexual
Citation: Kuo I, Golin CE, Wang J, Haley DF, Hughes J, Mannheimer S, Justman J, Rompalo A, Frew PM, Adimora AA, Soto-Torres L, Hodder S; HPTN 064 Study Team. Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend. 2014 Jun 1;139:93-9. doi: 10.1016/j.drugalcdep.2014.03.007. Epub 2014 Mar 19. PMID: 24698079; PMCID: PMC4104540
Date: 06/01/2014
Retention strategies and factors associated with missed visits among low income women at increased
Citation: Haley DF, Lucas J, Golin CE, Wang J, Hughes JP, Emel L, El-Sadr W, Frew PM, Justman J, Adimora AA, Watson CC, Mannheimer S, Rompalo A, Soto-Torres L, Tims-Cook Z, Carter Y, Hodder SL; HPTN 064 Study Team. Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064). AIDS Patient Care STDS. 2014 Apr;28(4):206-17. doi: 10.1089/apc.2013.0366. PMID: 24697160; PMCID: PMC3985524
Date: 04/15/2014
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected
Citation: Sulkowski MS1, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ; AIDS Clinical Trials Group A5277 Protocol Team. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis. 2014 Mar 1;209(5):658-67. doi: 10.1093/infdis/jit503. Epub 2013 Sep 16.
Date: 03/01/2014
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2
Citation: Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21. PMID: 24145879; PMCID: PMC3890333
Date: 02/01/2014
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of
Citation: McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):167-74. doi: 10.1097/01.qai.0000437171.00504.41. PMID: 24121755. PMCID: PMC3943548
Date: 02/01/2014
NIMH Project Accept (HPTN 043): results from in-depth interviews with a longitudinal cohort of
Citation: Maman S, van Rooyen H, Stankard P, Chingono A, Muravha T, Ntogwisangu J, Phakathi Z, Srirak N, F Morin S; NIMH Project Accept (HPTN 043) study team. NIMH Project Accept (HPTN 043): results from in-depth interviews with a longitudinal cohort of community members. PLoS One. 2014 Jan 29;9(1):e87091. doi: 10.1371/journal.pone.0087091. eCollection 2014. 10.1371/journal.pone.0087091. eCollection 2014. PMID: 24489841; PMCID: PMC3906114
Date: 01/29/2014
- ‹ First < 20 21 22 23 24 > Last ›